Overview

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medical University of Vienna
Collaborator:
Roche Pharma AG
Treatments:
Bisoprolol
Telmisartan